Dr. Prashant Mehta

Senior Consultant

18 years of experience

Bone Marrow Transplant Surgeons, Medical Oncologists

MBBS, MD, DM, Fellowship

Book an Appointment

About Dr. Prashant Mehta

Dr. Prashant Mehta is a widely experienced Medical Oncologist and Bone Marrow Transplant Physician. He focuses on Acute Leukemia, Lymphoma, and Bone Marrow Transplantation, including haploidentical and reduced toxicity transplants.

Education

Senior Consultant and Head of Department, Asian Inst. of Medical Sciences, 2022 Consultant, Artemis Hospitals, 2016 Associate Consultant, Artemis Health Inst., 2016

Training & Certificates

MBBS, Maulana Azad Medical Coll. (MAMC), Delhi, 2006 MD (Medicine), Lady Hardinge Medical Coll., Delhi, 2010 DM (Medical Oncology), All India Inst. of Medical Sciences (AIIMS) Delhi, 2014 Fellowship in Blood and Marrow Transplantation, Univ. of Washington - School of Medicine, 2017 Visiting Physician Fellowship in BMT/Cellular Therapy, Fred Hutchinson Cancer Research Center, Seattle, USA, 2017

Past Experience

Mehta P, Arora R. Clofarabine-based conditioning for T-cell replete haploidentical hematopoietic stem cell transplant for relapsed/refractory acute leukemia using peripheral blood stem cell grafts and post-transplantation cyclophosphamide. Cancer Res Stat Treat [serial online] 2020 [cited 2022 Jul 28];3:614-7. Available from: https://www.crstonline.com/text.asp?2020/3/3/614/295513 Mehta P et al. Utility of Serial Measurement of Serum C-Reactive Protein and Procalcitonin in Patients Undergoing HSCT https://tct.confex.com/tct/2020/meetingapp.cgi/publication/14986 Prashant Mehta, Rahul Arora, Swati Pabbi. Feasibility of Cyclosporine Instead of Tacrolimus after Haploidentical Transplantation Using PBSC Grafts with Post-Transplant Cyclophosphamide for Hematological MalignanciesBiology of Blood and Marrow Transplantation, Volume 26, Issue 3, Supplement,2020, Page S279, https://doi.org/10.1016/j.bbmt.2019.12.545. Mehta P, Bothra SJ. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23. PMID: 34844716. Mehta P et al." Oncotype DX: Where Does It Stand in India?." Journal of Global Oncology, 5, pp. 1–2 © 2019 by American Society of Clinical Oncology Patel A, Mehta P, Tannock IF, Srivastava P, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is Its Practice Changing? Facts and Facets. JCO Glob Oncol. 2020;6:382-386. doi:10.1200/JGO.19.00341 Bahl A, Talwar V, Sirohi B, Mehta P, Arya D, Shrivastava G, Dahiya A and Pavithran K (2020) Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Front. Oncol. 10:964. doi: 10.3389/fonc.2020.00964 . Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal cancer chemotherapy during the COVID-19 pandemic. Indian J Med Paediatr Oncol Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Patel A, Bhethanabhotla S, Batra A, Pramanik R, Gupta VG, Das CK, Mahindru S. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India?. Indian J Med Paediatr Oncol 2020;41:149-52 Mahindru S, Das CK, Patel A, Mehta P, Biswas B, Batra A, Bandhopadhyay A. Cancer surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian J Med Paediatr Oncol 2020;41:144-8 Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, Batra A, Mehta P. Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian J Med Paediatr Oncol 2020;41:141-3 Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, Biswas B, Batra A, Gupta VG, Das CK, Mahendru S. Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective. Indian J Med Paediatr Oncol 2020;41:153-5 Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, Gangulay S, Gupta VG. Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India. Indian J Med Paediatr Oncol 2020;41:132-4 Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, Das CK. Breast cancer treatment during the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:135-7 Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Pramanik R, Bhethanabhotla S, Gupta VG. How I treat epithelial ovarian cancer during the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:138-40 Srivastava P, Tilak T V, Patel A, Das CK, Biswas B, Mahindru S, Pramanik R, Ghosh J, Mehta P. Advisory for cancer patients during the COVID pandemic. Cancer Res Stat Treat 2020;3, Suppl S1:145-8 Das CK, Mehta P et al. Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter professional experience from India.https://meetinglibrary.asco.org/record/186667/abstract Mehta P, Parikh P, Aggarwal S, Batra A, Patel A, Kulkarni P, et al. Has India met this enemy before? From an eternal optimist's perspective: SARS-CoV-2. Indian J Med Sci 2020;72(1):8-12. Parikh PM, Mehta P, Krishna Mohan MVT, Bhattacharya G S, Govind Babu K. "Serious Adverse Events" faced by clinical trials: Impact of the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:127-31 Mehta P, Bhajoni PS, Mehta SP. Fighting cancer through an informed society. J Soc Health Diabetes 2016 [cited 2017 Jan 31];4:57-66 Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year professional experience of a single Inst. in India. ; J Clin Oncol 32, 2014 (suppl; abstr e19536) Ajay Gogia, Prashant Mehta, Raja Pramanik, Rajive Kumar. Isolated Breast Relapse Mimicking Breast Cancer in Elderly Patient with Acute Lymphoblastic Leukemia; Turk J Hematol 2014;31:203-204. Ajay Gogia, Prashant Mehta, Ritu Gupta, et al.Chronic lymphocytic leukemia with massive ascites: An unusual presenting manifestation; South Asian J Cancer. 2014 Oct-Dec; 3(4): 235–236. Gogia A, Raina V, Kumar L, Sharma A, Mehta P, Sharma MC. Diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia: A single-center professional experience. South Asian J Cancer 2014;3:186. Gogia A, Mehta P, et al.Cryptococcal meningitis in chronic lymphocytic leukemia; Indian J Cancer. 2013 Oct-Dec;50(4):301 Ankur Bahl, Prashant Mehta, and Vinod Raina. Severe Eosinophilia in Metastatic Carcinoma Breast: A Rare Paraneoplastic Phenomenon; Eur J clin med onc ,sept 2012. Mehta P, Rohtagi A, Sharma S K., et al. A case report of Rheumatoid Arthritis presenting with Right Heart Failure due to Pulmonary Artery Hypertension; Max Med J; vol 4,1, 2009, 7-9. Mehta P, Rohtagi A, Sharma S K., et al. A case of Mixed connective Tissue Disease presenting with alopecia Ind. J. Clin Pr, Vol. 19, 9, 2009; 37-39. Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year professional experience of a single Inst. in India. ; under consideration in National Medical Journal of IndiaMEHTA, Prashant; BHAJONI, Pranjit Santonu; MEHTA, Swati Pabbi. Response to afatinib, after gefitinib and erlotinib, in a patient with advanced adenocarcinoma of the lung with brain metastasis: A case report. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 1, p. 22-24, Jan. 2017. PARIKH, Purvish M, Mehta P. et al. Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 2, p. 47-57, Jun. 2017

Awards

Dr. Prashant Mehta is a distinguished Medical Oncologist and Bone Marrow Transplant Physician with more than 18 years of professional experience. He focuses on Acute Leukemia and Lymphoma in both children and adults, as well as Bone Marrow Transplantation, including haploidentical and reduced toxicity transplants. He pioneered the first Bone Marrow Transplant, Total Body irradiation-based transplant, and MUD transplant in the Faridabad region. He is skilled in immunotherapy and precision oncology, employing these techniques effectively when suitable. Dr. Mehta serves as the Clinical lead for various areas, including Lymphoid neoplasms, Haploidentical BMT in adults and children, Lung cancer, gynecological cancer, sarcoma, and melanoma. His educational qualification includes MBBS from Maulana Azad Medical Coll. (MAMC), Delhi, 2006. He is an alumnus of Maulana Azad Medical Coll. (MAMC), New Delhi, where he received the Meghna Krishna Baweja accolade for all-round excellence. He further achieved MD (Medicine) from Lady Hardinge Medical Coll., Delhi, 2010, and DM (Medical Oncology) from All India Inst. of Medical Sciences (AIIMS), Delhi, 2014. He also earned Fellowship in Blood and Marrow Transplantation from the Univ. of Washington - School of Medicine, 2017 and Visiting Physician Fellowship in BMT/Cellular Therapy from Fred Hutchinson Cancer Research Center, Seattle, USA, 2017. Dr. Mehta was honored with the Prof GS Bhattacharya accolade for Best All-rounder Oncologist in India in 2021 by the Indian Cooperative Oncology Network (ICON). He has served as a Principal Investigator for over 20 clinical trials and is a founding part of the 'Science and Cost' association, dedicated to enhancing cancer care access in India through scientific strategies. He has authored over 60 publications in national and international journals and serves as the Joint editor and web editor for the national oncology journal IJMPO. His research on dose optimization of Cytarabine during consolidation in Acute Myeloid Leukemia was presented at ESMO Asia, Singapore. He is actively involved in various national and international scientific societies, contributing significantly to advancements in oncology. Dr. Mehta is leading the cellular therapy program at Amrita Hosp. and is actively involved in making CAR-T cell therapies accessible in India. He is fluent in English, Hindi, and Punjabi.

Associations/Membership

ESMO Certified Medical Oncologist, European Society for Medical Oncology

Area of Expertise

Minimally Invasive Cancer Surgery

Let Us Help You Find The Best Doctor

Name*

Mobile Number*